Sarah Smith

Sarah Smith

Expertise: ESG Investing, Electric Vehicle Stocks, Short Squeeze Stocks

Education: BA, Government and Gender, Sexuality and Women’s Studies, The College of William & Mary

Awards & Accomplishments: Top 5% of stock pickers on TipRanks

About Sarah:
Sarah Smith is an experienced editor and writer who works to help retail investors make sense of what’s happening every day on Wall Street, and she’s particularly interested in ESG investing, EV stocks, and the rise of speculative trading activity like short squeezes. She has also written for Kiplinger.com, Smithsonian, and Washington City Paper. Sarah is currently working to become a Chartered Financial Analyst (CFA) and has already earned bachelor’s degrees in Government and Gender, Sexuality and Women’s Studies from the College of William and Mary. Her work for InvestorPlace.com focuses on helping investors understand the causes and impacts of daily stock and crypto market movements, and how a disruption in who invests – and how they invest – transforms the market. Sarah is recognized among the top 5% of stock pickers on TipRanks and has an average return of 50%. She lives in Arlington, Virginia.

Connect with Sarah on LinkedIn.

Recent Articles

FCEL Stock: Hydrogen Play FuelCell Continues to Soar Monday

FCEL stock has been on a tear in recent weeks. What do investors need to know about the latest move higher from FuelCell Energy?

CIIC Stock: Why Shares Are Surging Ahead of the Arrival SPAC Merger

CIIC stock is surging ahead of the Arrival SPAC merger thanks to Jim Cramer. Here's what you need to know now.

TSLA News: Tesla Stock Surges on $1,000 Price Target

Tesla stock just hit a new record thanks to Wedbush analyst Dan Ives. Here's what you need to know right now.

GRPEF Stock: Why Graphene NanoChem Is Soaring 40,000% Today

GRPEF stock is surging higher on Monday. But what do investors need to know about Graphene NanoChem and the graphene market?

REGN Stock: 11 Things for Investors to Know About Regeneron Approval

REGN stock is shifting the market today thanks to news its coronavirus treatment received emergency FDA approval.